WO2022189855 - 5-HT RECEPTOR AGONIST TITRATION
National phase entry:
Publication Number
WO/2022/189855
Publication Date
15.09.2022
International Application No.
PCT/IB2022/000103
International Filing Date
07.03.2022
Title **
[English]
5-HT RECEPTOR AGONIST TITRATION
[French]
TITRAGE D'AGONISTES DU RÉCEPTEUR SÉROTONINERGIQUE
Applicants **
DIAMOND THERAPEUTICS INC.
100 King Street West, Suite 6200
Toronto, ON M5X 1B8, CA
Inventors
BLUMSTOCK, Judith
100 King Street West, Suite 6200
Toronto, ON M5X 1B8, CA
TYLER, William, James
100 King Street West, Suite 6200
Toronto, ON M5X 1B8, CA
SPROUSE, Jeffrey
100 King Street West, Suite 6200
Toronto, M5X 1B8, CA
Priority Data
63/297,668
07.01.2022
US
63/158,245
08.03.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1296 | |
| EPO | Filing, Examination | 8865 | |
| Japan | Filing | 503 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2360 |
Total: 13599 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed herein are methods of treating neuropsychiatric and cognitive conditions in individuals by titrating a 5-HT receptor agonist over a period of time to provide a therapeutic effective amount of the 5-HT receptor agonist to the individual.[French]
L'invention concerne des méthodes de traitement de troubles neuropsychiatriques et cognitifs chez des sujets, par titrage d'un agoniste du récepteur sérotoninergique sur une période de temps, en vue de fournir une quantité thérapeutiquement efficace de l'agoniste du récepteur sérotoninergique au sujet.